Boston Scientific (NYSE:BSX) Stock Gets Price Target Trim from BTIG Research

Boston Scientific (NYSE:BSX) had its target price lowered by BTIG Research from $56.00 to $49.00 in a report issued on Thursday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. JPMorgan Chase & Co. cut Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a report on Wednesday. Barclays upgraded Boston Scientific to a “hold” rating in a research note on Wednesday, October 7th. UBS Group cut their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Robert W. Baird lifted their target price on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Citigroup reduced their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Stock Performance

Shares of BSX opened at $41.93 on Thursday. The company has a market cap of $60.77 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. The firm has a 50-day moving average of $44.78 and a 200-day moving average of $56.88. Boston Scientific has a one year low of $39.57 and a one year high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. Boston Scientific’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 EPS. As a group, equities analysts forecast that Boston Scientific will post 3.17 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 189,522 shares of company stock valued at $9,157,810. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds have recently bought and sold shares of the stock. Bfsg LLC lifted its holdings in Boston Scientific by 3.7% during the 3rd quarter. Bfsg LLC now owns 7,867 shares of the medical equipment provider’s stock worth $343,000 after purchasing an additional 284 shares during the last quarter. Chicago Partners Investment Group LLC boosted its stake in Boston Scientific by 293.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 179,962 shares of the medical equipment provider’s stock valued at $8,222,000 after purchasing an additional 134,169 shares during the period. Covestor Ltd boosted its stake in Boston Scientific by 112.1% in the 3rd quarter. Covestor Ltd now owns 1,968 shares of the medical equipment provider’s stock valued at $86,000 after purchasing an additional 1,040 shares during the period. Richardson Financial Services Inc. grew its holdings in Boston Scientific by 6.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 9,735 shares of the medical equipment provider’s stock valued at $425,000 after buying an additional 550 shares in the last quarter. Finally, Ascent Group LLC grew its holdings in Boston Scientific by 29.0% in the 3rd quarter. Ascent Group LLC now owns 48,869 shares of the medical equipment provider’s stock valued at $2,133,000 after buying an additional 10,974 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.